company background image
SPL

Starpharma Holdings ASX:SPL Stock Report

Last Price

AU$0.66

Market Cap

AU$267.8m

7D

-6.4%

1Y

-37.6%

Updated

29 Jan, 2023

Data

Company Financials +

Starpharma Holdings Limited

ASX:SPL Stock Report

Mkt Cap: AU$267.8m

SPL Stock Overview

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.

SPL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Starpharma Holdings Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Starpharma Holdings
Historical stock prices
Current Share PriceAU$0.66
52 Week HighAU$1.11
52 Week LowAU$0.49
Beta0.87
1 Month Change19.09%
3 Month Change22.43%
1 Year Change-37.62%
3 Year Change-45.19%
5 Year Change-59.06%
Change since IPO-18.13%

Recent News & Updates

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Nov 22
We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Recent updates

We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Nov 22
We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation

Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

Mar 21
Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money

We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

Jan 26
We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely

We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Jun 21
We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth

Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

May 16
Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?

Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Mar 02
Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation

Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Feb 10
Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?

Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Jan 20
Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future

Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

Dec 28
Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?

How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Dec 07
How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?

Shareholder Returns

SPLAU PharmaceuticalsAU Market
7D-6.4%-4.4%0.6%
1Y-37.6%-25.2%3.5%

Return vs Industry: SPL underperformed the Australian Pharmaceuticals industry which returned -25.2% over the past year.

Return vs Market: SPL underperformed the Australian Market which returned 3.5% over the past year.

Price Volatility

Is SPL's price volatile compared to industry and market?
SPL volatility
SPL Average Weekly Movement8.6%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement8.5%
10% most volatile stocks in AU Market15.7%
10% least volatile stocks in AU Market3.5%

Stable Share Price: SPL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: SPL's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199650Jackie Fairleyhttps://starpharma.com

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray.

Starpharma Holdings Limited Fundamentals Summary

How do Starpharma Holdings's earnings and revenue compare to its market cap?
SPL fundamental statistics
Market CapAU$267.80m
Earnings (TTM)-AU$16.15m
Revenue (TTM)AU$5.16m

51.9x

P/S Ratio

-16.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SPL income statement (TTM)
RevenueAU$5.16m
Cost of RevenueAU$14.46m
Gross Profit-AU$9.29m
Other ExpensesAU$6.86m
Earnings-AU$16.15m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.04
Gross Margin-180.05%
Net Profit Margin-312.94%
Debt/Equity Ratio8.3%

How did SPL perform over the long term?

See historical performance and comparison